# A Study of GR1014 Cutaneous Gel for the Prevention of Skin Reactions Caused by Radiation Therapy for Breast Cancer

Source: https://onco.cc/trials/nct07192588/  
OnCo record `nct07192588` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of GR1014-CG 2.4% in advanced solid tumours, run by Graegis Pharmaceuticals Ltd, active and no longer recruiting.

## Summary

A Study of GR1014 Cutaneous Gel for the Prevention of Skin Reactions Caused by Radiation Therapy for Breast Cancer is a phase 2 interventional study registered as NCT07192588 by Graegis Pharmaceuticals Ltd, with 273 participants enrolled, started 2024-07-26 and due to reach its primary completion in 2026-09-30. Interventions recorded: GR1014-CG 2.4%, Vehicle Gel, Radiation Therapy and GR1014-CG 4.7%.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07192588
- Phase: 2
- Setting: A Randomised, Double-Blind, Vehicle-Controlled, Multi-Centre, Parallel-Group Study to Investigate the Safety, Tolerability, and Efficacy of GR1014 Cutaneous Gel as a Topical Radioprotector in the Prevention of the Radiodermatitis Occurring With Adjuvant Radiotherapy for Localised Breast Cancer After Lumpectomy
- Sponsor: Graegis Pharmaceuticals Ltd
- Enrolled: 273

## Sources

- ClinicalTrials.gov NCT07192588: https://clinicaltrials.gov/study/NCT07192588

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)

---
JSON: https://onco.cc/api/v1/entities/nct07192588.json